Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Notice of Conference Call the Day Before

<< Previous

Bullboard Posts

Next >>

Comment by venture009on Nov 11, 2024 11:26am

62 Views

Post# 36306623

RE:RE:RE:Notice of Conference Call the Day Before

At the moment there is very little enthusiasm for this stock, so if they don't have something of substance to report the sp will suffer. Any suggestion of a reverse split will be a death nil for this company.

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant